what is Melanotan II?

the Hruby-Hadley collaboration

In the early 1990s, Victor Hruby (chemistry) and Mac Hadley (anatomy/physiology) at the University of Arizona synthesized Melanotan II as a shorter, more potent analogue of α-melanocyte-stimulating hormone (α-MSH). Their collaboration extended work begun in 1980 with the linear analogue NDP-MSH, which was ~26 times more potent than native α-MSH and had ultralong biological activity (Sawyer et al., 1980).

why a sunless tanner

The original research goal was a sunless tanning agent that could reduce UV exposure and skin cancer risk. By activating MC1R directly, the team hoped to drive eumelanin production without the DNA damage that accompanies UV-induced tanning (Hadley & Dorr, 2006).

the selectivity tradeoff

Unlike its predecessor Melanotan I (afamelanotide), which is a linear 13-amino-acid peptide with selective MC1R binding, MT-II was designed as a cyclic heptapeptide constrained by a lactam bridge between Asp5 and Lys10 side chains (Al-Obeidi et al., 1989; Hruby et al., 1995). The cyclization produced over 1000-fold higher potency than native α-MSH in frog skin bioassays -- but at the cost of receptor selectivity. That tradeoff shaped everything that followed.

a cyclic seven-residue scaffold

Melanotan II is a cyclic heptapeptide (seven amino acids) that binds with meaningful affinity to MC1R, MC3R, MC4R, and MC5R. This non-selective binding profile is what distinguishes it from afamelanotide (primarily MC1R) and bremelanotide/PT-141 (primarily MC4R, derived from MT-II research) (Cone, 2003; Hruby et al., 1995).

one peptide, four receptors

• MC1R: drives pigmentation on melanocytes; highest-affinity MT-II target (Ki ~0.67 nM).
• MC3R: hypothalamic energy homeostasis and nutrient partitioning.
• MC4R: central appetite and sexual-function modulation (Cone, 2003).
• MC5R: exocrine and sebaceous gland regulation.
• MC2R: the ACTH receptor in the adrenal cortex; MT-II essentially does not bind it, which spares the cortisol axis.

why "non-selective" matters

Activating four melanocortin receptors simultaneously creates a broad and unpredictable effect profile. Tanning, appetite suppression, and sexual arousal all rise and fall together -- lowering the dose does not isolate one effect, it scales all of them down proportionally (Catania et al., 2004).

regulator-by-regulator status

• FDA: classified as an unapproved new drug; warnings reiterated as recently as 2024.
• TGA (Australia): explicitly illegal; flagged for serious long-term health risks.
• MHRA (UK): sale or advertising breaches the Human Medicines Regulations 2012.
• EMA (EU): no marketing-authorization application has ever been filed for MT-II.
• HPRA (Ireland): removed 500+ social-media listings between July 2022 and June 2023.

the gray-market quality gap

Products sold online as "MT-II" or "Melanotan 2" are unregulated research chemicals with no standardized manufacturing, purity testing, or dosing guidance. Independent analysis of gray-market vials has found over 100 unidentified ingredients alongside the nominal peptide, versus ~10 in a licensed medication (Evans-Brown et al., 2012; Fink et al., 2017).

The gap between published receptor pharmacology and gray-market product quality is enormous -- knowing what MT-II does in a controlled assay tells you very little about what is actually in a given vial.

α-MSH: the parent hormone

All melanocortin-based peptides trace back to α-MSH, a 13-amino-acid hormone cleaved from POMC by sequential prohormone convertase processing (Catania et al., 2004). Every drug in this family is, in essence, a redesign of that 13-residue scaffold.

three siblings, three fates

• Melanotan I (afamelanotide / SCENESSE): linear 13-residue analogue, selective for MC1R, FDA-approved in 2019 for erythropoietic protoporphyria.
• Melanotan II: cyclic 7-residue analogue, non-selective across MC1R-MC5R, never approved by any regulator.
• PT-141 (bremelanotide / Vyleesi): cyclic MT-II metabolite differing only by a C-terminal hydroxyl in place of the amide; FDA-approved in 2019 for HSDD in premenopausal women.

the PT-141 pivot

Palatin Technologies abandoned MT-II as a drug candidate in 2000 and patented PT-141, optimizing the scaffold for MC4R activity while reducing the broader melanocortin agonism that drove MT-II's nausea and pigmentation effects (Diamond et al., 2006). PT-141 is the only FDA-approved drug to emerge from the MT-II lineage. Cryo-EM of MC4R-Gs complexes now confirms how selective MC4R activation is achievable at the structural level (Yu et al., 2021).

The formal clinical program for MT-II was abandoned before any Phase III trials were designed. Palatin Technologies pivoted to PT-141 around 2000, leaving MT-II's human safety and efficacy record permanently incomplete. What exists -- a handful of small pilots, gray-market case reports, and animal pharmacology data -- cannot establish safe dosing ranges, long-term carcinogenicity risk, or reliable adverse-event incidence rates for a non-selective MC1R/MC4R agonist circulating exclusively in unregulated gray-market vials.

Unit 2 is the natural next step: it maps exactly how MT-II binds MC1R, MC3R, MC4R, and MC5R -- explaining why the non-selective pharmacology produces such a wide and hard-to-control effect profile, and why that selectivity gap is the reason selective descendants like bremelanotide succeeded where MT-II did not.